Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Medacta Group SA
  6. News
  7. Summary
    MOVE   CH0468525222

MEDACTA GROUP SA

(MOVE)
  Report
Delayed Swiss Exchange  -  11:30 2022-12-08 am EST
99.30 CHF   +0.10%
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Deport Walmart...
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Medacta Group SA Revises Revenue Growth Guidance for the Full Year 2022

09/09/2022 | 01:00am EST

Medacta Group SA revised upward 2022 revenue growth guidance in the range of 14% to 16%, at constant currency. This compares to previous outlook of revenue growth towards 14%.


ę S&P Capital IQ 2022
All news about MEDACTA GROUP SA
11/15Global markets live: Amazon, Berkshire Hathaway, Infineon, Home Depo..
MS
11/15Medacta Settles Patent Disputes Over Knee, Shoulder Implants With Conformis
MT
11/15Medacta Group SA announces the final settlement in the Conformis case
EQ
11/06Medacta Says First US Hip Surgery Carried Out With Double Mobility Converter
MT
11/04Medacta Group Sa : Medacta Expands its Hip Offerings with New Cobalt-Free SensiTiN™ ..
EQ
10/12Medacta NextAR Spine wins the 2022 Spine Technology Award from Orthopedics This Week du..
EQ
10/05Medacta's MySpine Anchor Technology Used in First US Procedure
MT
10/05Medacta announces the first MySpine Anchor procedure completed in the US
EQ
09/21Medacta's MyKnee R Platform Becomes Part Of Revision Surgeries In US
MT
09/21Medacta announces first revision surgeries in the US using the unique-on-the-market and..
EQ
More news
Analyst Recommendations on MEDACTA GROUP SA
More recommendations
Financials
Sales 2022 429 M 452 M 452 M
Net income 2022 56,2 M 59,2 M 59,2 M
Net Debt 2022 123 M 130 M 130 M
P/E ratio 2022 35,7x
Yield 2022 0,59%
Capitalization 2 011 M 2 121 M 2 121 M
EV / Sales 2022 4,98x
EV / Sales 2023 4,35x
Nbr of Employees 1 421
Free-Float 30,4%
Chart MEDACTA GROUP SA
Duration : Period :
Medacta Group SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDACTA GROUP SA
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 100,66 €
Average target price 107,65 €
Spread / Average Target 6,95%
EPS Revisions
Managers and Directors
Francesco Siccardi Chief Executive Officer
Corrado Farsetta Chief Financial Officer
Alberto Siccardi Non-Executive Chairman
Victor Waldemar Balli Lead Independent Non-Executive Director
Philippe A. Weber Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
MEDACTA GROUP SA-30.14%2 109
ABBOTT LABORATORIES-25.53%182 744
MEDTRONIC PLC-25.49%102 304
BECTON, DICKINSON AND COMPANY0.29%69 846
DEXCOM, INC.-12.97%45 544
HOYA CORPORATION-21.30%35 092